
MaaT Pharma Presents Updated Positive Data in Early Access Program for Xervyteg® at the EHA Congress
The Company, a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with...